Vanderbilt HIV Clinical Trials Unit

说明（由申请人提供）：30多年来，艾滋病毒流行病是对健康和发展的最大持续威胁之一。niaid资助的临床试验网络在协调应对艾滋病毒/艾滋病领域的关键研究问题方面发挥了关键作用。拟议中的范德比尔特临床试验单位（CTU）是范德比尔特大学和华盛顿大学之间的合作伙伴关系，包括三个表现最好的现任临床研究站点（CRSs），跨越艾滋病临床试验小组（ACTG）的治疗任务和艾滋病毒疫苗试验网络（HVTN）的疫苗任务。这建立在Vanderbilt Therapeutics CRS和Vanderbilt Vaccine CRS之间已经建立的伙伴关系的基础上，并增加了与Washington University Therapeutics CRS的新伙伴关系。后两个地点自1987-1988年HVTN和ACTG成立以来一直是这两个网络的成员。该CTU的领导人在人类基因组学和艾滋病毒疾病的神经学方面等领域为该网络作出了影响深远、独特的科学和规划贡献。今后，CTU将继续利用范德比尔特大学在生物医学信息学方面的机构优势，实施灵活、实时、可共享的信息学工具，从而继续发挥其项目影响的记录

DESCRIPTION (provided by applicant): The HIV pandemic is one of the greatest ongoing threats to health and development, over 30 years past its recognition. The NIAID-funded Clinical Trials Networks have played critical roles in the coordinated response to key research questions in the HIV/AIDS field. The proposed Vanderbilt Clinical Trials Unit (CTU) is a partnership between Vanderbilt University and Washington University, comprising three top-performing incumbent Clinical Research Sites (CRSs) that span the therapeutics mission of the AIDS Clinical Trials Group (ACTG) and the vaccine mission of the HIV Vaccine Trials Network (HVTN). This builds upon the already established partnership between the Vanderbilt Therapeutics CRS and the Vanderbilt Vaccine CRS, and adds a new partnership with the Washington University Therapeutics CRS. The latter two sites have been members of the HVTN and ACTG since the inception of these Networks in 1987-1988. The leaders of this CTU have made high-impact, unique scientific and programmatic contributions to the Networks in areas that include human genomics and neurological aspects of HIV disease. Moving forward this CTU will continue its track record of programmatic impact by leveraging Vanderbilt's institutional strength in biomedical informatics to implement flexible, real-time, shareable informatics tools to optimize CTU performance. This CTU also benefits from close ties to other major NIH programs including Vanderbilt's roles as Coordinating Center for the nationwide network of approximately 60 Clinical and Translational Science Awards (CTSA), for the seven worldwide regions of the NIAID-sponsored International Epidemiologic Databases to Evaluate AIDS (leDEA), and for the seven countries of leDEA's Latin American region. During the proposed finding period the Vanderbilt CTU will make substantial contributions to the ACTG's scientific priorities focused on HIV/AIDS, tuberculosis, and viral hepatitis, and will make substantial contributions to the HVTN's major scientific priority of developing and testing a safe and effective vaccine for HIV. RELEVANCE: Public health will benefit from Vanderbilt Clinical Trials Unit's efforts in support of developing highly effective prevention and treatment strategies for HIV infection, tuberculosis, and viral hepatitis.